Join to access to all OVN content. Join for Free
My GOAL is to be a Medical Science Liaison
Medical Science Liaison pharmaceutical sales career progression networking in medical field MSL career advice

My GOAL is to be a Medical Science Liaison


Share This Article


Summary

In this episode, Jeremy McLemore shares his inspiring journey from pharmaceutical sales to becoming a Medical Science Liaison (MSL). Jeremy discusses his transition into the MSL role, detailing how he discovered the position and pursued it despite setbacks. He reflects on his experiences at Bristol Myers Squibb and AbbVie, highlighting the importance of networking, adaptability, and resilience in career progression. Jeremy also compares sales and MSL roles, offering insights into the unique challenges of each. He concludes with valuable advice for aspiring MSLs and shares his future goals.

Jeremy McLemore, Medical Science Liaison at AbbVie, discusses how his goal was to be an MSL and how he got there.

Jeremy shares….

How he approached his career from PharmD onward

The importance of being flexible and adaptable

Why it makes sense to consider a “starter” Industry role

How sales and field medical affairs differ (and how they are alike)

Click for Source
Medical Science Liaison, pharmaceutical sales, career progression, networking in medical field, MSL career advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN